福建省两地区百日咳鲍特菌抗原基因型特征及耐药性分析

doi:10.12372/jcp.2025.25e0425

Abstract

Abstract:

Objective To analyze the genetic polymorphism of antigenic genes and antimicrobial resistance phenotypes of Bordetella pertussis (BP) in Fuzhou and Youxi, Fujian Province, China, and to provide scientific evidence for optimizing vaccination strategies and antibiotic use. Methods A total of 336 nasopharyngeal swab specimens from suspected pertussis cases were collected from both regions in 2024. Bacterial culture, isolation, and identification were performed. Polymorphism and mutations were determined by analyzing seven antigenic genes (ptxP, ptxA, ptxC, prn, fim3, fim2, tcfA) and the 23S rRNA A2047 locus. A maximum-likelihood phylogenetic tree was constructed based on core-genome single nucleotide polymorphisms (cgSNPs). The minimum inhibitory concentrations (MICs) of macrolides, sulfonamides, and β-lactams were determined using the E-test method. Results Twenty-nine BP clinical isolates were successfully obtained (8.6%, 29/336). Antigenic gene profiling revealed that the predominant genotype was ptxP3/prn2/ptxC1/ptxA1/fim2-1/fim3-1/tcfA2 (55.2%, 16/29), with ptxP3/prn2/ptxA1 strains accounting for 72.4% (21/29). Four prn150 mutant strains were identified (13.8%, 4/29). Phylogenetic analysis demonstrated that the vaccine strain CS formed an independent evolutionary branch (Cluster A). The 2024 Fujian isolates exhibited significant genetic divergence from pre-2020 domestic strains, forming two major clusters: Cluster B (ptxP3/prn2/ptxA1, containing most Fujian isolates) and Cluster C (ptxP1/prn1/ptxA1, comprising historical isolates). The 23S rRNA A2047G mutation conferring macrolide resistance was detected in all isolates, with MICs > 90 mg/L. MICs for TMP-SMX ranged from 0.005 to 0.45 mg/L. MICs for β-lactams (ceftriaxone, cefotaxime, cefoperazone/sulbactam) ranged from 0.004 to 0.64 mg/L. Conclusion The epidemic strains of BP circulating in Fujian exhibit distinct antigenic gene evolutionary patterns and widespread macrolide resistance. These findings highlight the urgent need to strengthen molecular genotyping-based surveillance of vaccine components and optimize antimicrobial therapy based on susceptibility profiles.

Key words: pertussis, Bordetella pertussis, antigenic genotype, whole-genome sequencing, macrolide resistance, child

CLC Number:

SHI Xiaosong, FU Shijie, HE Xiaohua, LYU Hui, CHEN Houyang, CHEN Maolin, CHEN Jie. Antigenic genotypic characteristics and antibiotic resistance analysis of Bordetella pertussis in two regions of Fujian province[J].Journal of Clinical Pediatrics, 2025, 43(8): 575-582.

Figures/Tables 3

References 41

[1]	中华预防医学会, 中华预防医学会疫苗与免疫分会. 中国百日咳行动计划专家共识[J]. 中华流行病学杂志, 2021, 42(6): 955-965.
	Association Chinese Preventive Medicine, Association Vaccine and Immunology Branch of the Chinese Preventive Medicine. Expert consensus on the China Pertussis Initiative[J]. Zhonghua Liuxingbingxue Zazhi, 2021, 42(6): 955-965.
[2]	Kuchar E, Karlikowska-Skwarnik M, Han S, et al. Pertussis: history of the disease and current prevention failure[J]. Adv Exp Med Biol, 2016, 934: 77-82. doi: 10.1007/5584_2016_21 pmid: 27256351
[3]	华春珍, 王传清, 杨章女, 等. 百日咳病原新认识及其抗感染策略[J]. 临床儿科杂志, 2024, 42(6): 480-484.
	Hua CZ, Wang CQ, Yang ZY, et al. New insights into the pathogen of pertussis and strategies for antibacterial infection[J]. Linchuang Erke Zazhi, 2024, 42(6): 480-484.
[4]	国家疾病预防控制局. 2024年12月全国法定传染病疫情概况[EB/OL]. [2025-04-01]. https://www.ndcpa.gov.cn/jbkzzx/c100016/common/content/content_1879707944644890624.html.
	National Disease Control and Prevention Administration. National Report on Legally Notifiable Infectious Diseases in December 2024 [EB/OL]. [2025-04-01]. https://www.ndcpa.gov.cn/jbkzzx/c100016/common/content/content_1879707944644890624.html.
[5]	贾海梅, 陈杨伟, 王清华, 等. 2018-2022年福建省福州市百日咳流行病学特征及防控策略探讨[J]. 疾病监测, 2024, 39(5): 571-575.
	Jia HM, Chen YW, Wang QH, et al. Epidemiological characteristics and prevention and control strategies of pertussis in Fuzhou, Fujian province 2018-2020[J]. Jibing Jiance, 2024, 39(5): 571-575.
[6]	Liu Y, Yu D, Wang K, et al. Global resurgence of pertussis: A perspective from China[J]. J Infect, 2024, 89(5): 106289.
[7]	张梦瑶, 何美燕, 左伟伦, 等. 云南西双版纳百日咳博德特氏菌分离株抗原基因特征分析[J]. 中国公共卫生, 2023, 39(2): 245-248.
	Zhang MY, He MY, Zuo WL, et al. Antigenic gene characteristics of Bordetella pertussis isolates from child patients in Xishuangbanna, Yunnan province: a comparative analysis[J]. Zhongguo Gonggong Weisheng, 2023, 39(2): 245-248.
[8]	Wu S, Hu Q, Yang C, et al. Molecular epidemiology of Bordetella pertussis and analysis of vaccine antigen genes from clinical isolates from Shenzhen, China[J]. Ann Clin Microbiol Antimicrob, 2021, 20(1): 53.
[9]	李振翠, 马炜森, 王安娜, 等. 广东省两个地区2021-2022年百日咳鲍特菌分离株的抗菌药物敏感性和抗原基因型[J]. 中国疫苗和免疫, 2023, 29(5): 498-502.
	Li ZC, Ma WS, Wang AN, et al. Antimicrobial susceptibility and antigen genotypes of Bordetella pertussis strains isolated in two prefectures of Guangdong province in 2021-2022[J]. ZhongGuo Yimiao He Mianyi, 2023, 29(5): 498-502.
[10]	中华医学会感染病学分会儿科感染学组, 国家卫生健康委能力建设和继续教育儿科专委会感染组, 中国临床实践指南联盟方法学专委会, 等. 中国百日咳诊疗与预防指南(2024版)[J]. 中华医学杂志, 2024, 104(15): 1258-1279.
	Pediatric Infection Group Chinese Society of Infectious Diseases, Chinese Medical Association, Infection Group Pediatric Expert Committee of National Health Commission Capacity Building and Continuing Education, Committee China Clinical Practice Guidelines Alliance Methodology, et al. Guidelines for diagnosis and management and prevention of pertussis of China (2024 edition)[J]. Zhonghua Yixue Zazhi, 2024, 104(15): 1258-1279.
[11]	van der Zee A, Schellekens JF, Mooi FR. Laboratory diagnosis of pertussis[J]. Clin Microbiol Rev, 2015, 28(4): 1005-1026. doi: 10.1128/CMR.00031-15 pmid: 26354823
[12]	Yang Y, Yao K, Ma X, et al. Variation in Bordetella pertussis susceptibility to erythromycin and virulence-related genotype changes in China (1970-2014)[J]. PLoS One, 2015, 10(9): e0138941.
[13]	Xie J, Chen Y, Cai G, et al. Tree Visualization By One Table (tvBOT): a web application for visualizing, modifying and annotating phylogenetic trees[J]. Nucleic Acids Res, 2023, 51(W1): W587-W592.
[14]	Lin X, Zou J, Yao K, et al. Analysis of antibiotic sensitivity and resistance genes of Bordetella pertussis in Chinese children[J]. Medicine (Baltimore), 2021, 100(2): e24090.
[15]	CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 33rd ed. CLSI Standards M100[S]. Malvern, Pennsylvania, USA: Clinical and Laboratory Standards Institute, 2023.
[16]	Etskovitz H, Anastasio N, Green E, et al. Role of evolutionary selection acting on vaccine antigens in the re-emergence of Bordetella pertussis [J]. Diseases, 2019, 7(2): 35.
[17]	Heikkinen E, Xing DK, Olander RM, et al. Bordetella pertussis isolates in Finland: serotype and fimbrial expression[J]. BMC Microbiol, 2008, 8: 162. doi: 10.1186/1471-2180-8-162 pmid: 18816412
[18]	de Paula VG, de Sousa RS, da Silva R, et al. fim3-24/ptxP-3 genotype is associated to whooping cough outbreak in Brazilian Midwest: the selection of Bordetella pertussis strains driven by vaccine immunization[J]. Infect Genet Evol, 2024, 121: 105599.
[19]	Xu Z, Hu D, Luu LDW, et al. Genomic dissection of the microevolution of Australian epidemic Bordetella pertussis [J]. Emerg Microbes Infect, 2022, 11(1): 1460-1473.
[20]	Ring N, Davies H, Morgan J, et al. Comparative genomics of Bordetella pertussis isolates from New Zealand, a country with an uncommonly high incidence of whooping cough[J]. Microb Genom, 2022, 8(1): 000756.
[21]	Zomer A, Otsuka N, Hiramatsu Y, et al. Bordetella pertussis population dynamics and phylogeny in Japan after adoption of acellular pertussis vaccines[J]. Microb Genom, 2018, 4(5): e000180.
[22]	Schmidtke AJ, Boney KO, Martin SW, et al. Population diversity among Bordetella pertussis isolates, United States, 1935-2009[J]. Emerg Infect Dis, 2012, 18(8): 1248-1255. doi: 10.3201/eid1808.120082 pmid: 22841154
[23]	Bouchez V, Guillot S, Landier A, et al. Evolution of Bordetella pertussis over a 23-year period in France, 1996 to 2018[J]. Euro Surveill, 2021, 26(37).
[24]	King AJ, van der Lee S, Mohangoo A, et al. Genome-wide gene expression analysis of Bordetella pertussis isolates associated with a resurgence in pertussis: elucidation of factors involved in the increased fitness of epidemic strains[J]. PLoS One, 2013, 8(6): e66150.
[25]	Hijnen M, de Voer R, Mooi FR, et al. The role of peptide loops of the Bordetella pertussis protein P.69 pertactin in antibody recognition[J]. Vaccine, 2007, 25(31): 5902-5914.
[26]	Li Z, Xiao F, Hou Y, et al. Genomic epidemiology and evolution of Bordetella pertussis under the vaccination pressure of acellular vaccines in Beijing, China, 2020-2023[J]. Emerg Microbes Infect, 2025, 14(1): 2447611.
[27]	Fu P, Zhou J, Meng J, et al. Emergence and spread of MT28 ptxP3 allele macrolide-resistant Bordetella pertussis from 2021 to 2022 in China[J]. Int J Infect Dis, 2023, 128: 205-211.
[28]	Safarchi A, Octavia S, Luu LD, et al. Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model[J]. Vaccine, 2015, 33(46): 6277-6281. doi: 10.1016/j.vaccine.2015.09.064 pmid: 26432908
[29]	Tsang RSW, Shuel M, Cronin K, et al. The evolving nature of Bordetella pertussis in Ontario, Canada, 2009-2017: strains with shifting genotypes and pertactin deficiency[J]. Can J Microbiol, 2019, 65(11): 823-830.
[30]	Otsuka N, Han HJ, Toyoizumi-Ajisaka H, et al. Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan[J]. PLoS One, 2012, 7(2): e31985.
[31]	Esposito S, Stefanelli P, Fry NK, et al. Pertussis prevention: reasons for resurgence, and differences in the current acellular pertussis vaccines[J]. Front Immunol, 2019, 10: 1344. doi: 10.3389/fimmu.2019.01344 pmid: 31333640
[32]	Hu Y, Zhou L, Du Q, et al. Sharp rise in high-virulence Bordetella pertussis with macrolides resistance in Northern China[J]. Emerg Microbes Infect, 2025, 14(1): 2475841.
[33]	Fu P, Yan G, Li Y, et al. Pertussis upsurge, age shift and vaccine escape post-COVID-19 caused by ptxP3 macrolide-resistant Bordetella pertussis MT28 clone in China[J]. Clin Microbiol Infect, 2024, 30(11): 1439-1446.
[34]	Ivaska L, Barkoff AM, Mertsola J, et al. Macrolide resistance in Bordetella pertussis: current situation and future challenges[J]. Antibiotics (Basel), 2022, 11(11).
[35]	Zhao H, Wei L, Li H, et al. Appropriateness of antibiotic prescriptions in ambulatory care in China: a nationwide descriptive database study[J]. Lancet Infect Dis, 2021, 21(6): 847-857. doi: 10.1016/S1473-3099(20)30596-X pmid: 33515511
[36]	Yao K, Deng J, Ma X, et al. The epidemic of erythromycin-resistant Bordetella pertussis with limited genome variation associated with pertussis resurgence in China[J]. Expert Rev Vaccines, 2020, 19(11): 1093-1099.
[37]	Li L, Deng J, Ma X, et al. High prevalence of macrolide-resistant Bordetella pertussis and ptxP1 genotype, Mainland China, 2014-2016[J]. Emerg Infect Dis, 2019, 25(12): 2205-2214.
[38]	Hua CZ, Wang HJ, Zhang Z, et al. In vitro activity and clinical efficacy of macrolides, cefoperazone-sulbactam and piperacillin/piperacillin-tazobactam against Bordetella pertussis and the clinical manifestations in pertussis patients due to these isolates: a single-centre study in Zhejiang Province, China[J]. J Glob Antimicrob Resist, 2019, 18: 47-51.
[39]	Cimolai N. Pharmacotherapy for Bordetella pertussis infection. II. A synthesis of clinical sciences[J]. Int J Antimicrob Agents, 2021, 57(3): 106257.
[40]	Mi YM, Hua CZ, Fang C, et al. Effect of macrolides and β-lactams on clearance of Bordetella pertussis in the nasopharynx in children with whooping cough[J]. Pediatr Infect Dis J, 2021, 40(2): 87-90.
[41]	许示沂, 杜敏, 白丽霞, 等. 婴幼儿重症百日咳研究进展[J]. 临床儿科杂志, 2025, 43(5): 383-388.
	Xu SY, Du M, Bai LX, et al. Research progress on severe pertussis in infants and young children[J]. Linchuang Erke Zazhi, 2025, 43(5): 383-388.

基因型	菌株编号	总计n（%）
ptxP3/prn2/ptxC1/ptxA1/fim2-1/fim3-1/tcfA2	Fujian_8、9、10、11、13、14、15、17、20、21、22、23、24、25、26、27	16（55.2）
ptxP3/prn2/ptxC2/ptxA1/fim2-1/fim3-1/tcfA2	Fujian_2、3、5、6、7	5（17.2）
ptxP1/prn1/ptxC1/ptxA1/fim2-1/fim3-1/tcfA2	Fujian_12、16、18、19	4（13.8）
ptxP3/prn150/ptxC1/ptxA1/fim2-1/fim3-1/tcfA2	Fujian_28、29	2（6.9）
ptxP3/prn150/ptxC2/ptxA1/ fim2-1/fim3-3/tcfA2	Fujian_1、4	2（6.9）

抗菌药物	MIC范围/mg·L^-1	MIC₅₀/mg·L^-1	MIC₉₀/mg·L^-1
红霉素	>256	>256	>256
阿奇霉素	90~>256	120	>256
克拉霉素	>256	>256	>256
复方磺胺甲噁唑	0.005~0.45	0.15	0.30
头孢曲松	0.012~0.64	0.064	0.12
头孢噻肟	0.004~0.40	0.014	0.40
头孢哌酮/舒巴坦	0.02~0.12	0.042	0.082

Antigenic genotypic characteristics and antibiotic resistance analysis of Bordetella pertussis in two regions of Fujian province

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 41

Related Articles 15

Metrics

Comments

Recommended 0

[1]	PEI Pei, LI Weihua, HUAI Wan, YAO Ruen, GE Hejia, WANG Jiwen, WANG Xiumin, JI Wei, ZHOU Yunqing, HE Yingzhong, HAN Feng. Genetic and clinical characteristics analysis of 10 children with ATP1A2/ATP1A3 gene variants [J]. Journal of Clinical Pediatrics, 2025, 43(8): 590-597.
[2]	LI Heting, SUN Ruidi, JIANG Jun. Clinical features, prognosis and neurophysiological characteristics of children with acute anti-GQ1b antibody syndrome [J]. Journal of Clinical Pediatrics, 2025, 43(8): 604-609.
[3]	ZHANG Cheng, CAO Qiaoyu, ZHENG Luyao, LI Ming, GE Hongsong. Retrospective analysis of clinical features, dermoscopic characteristics and prognosis of acquired facial hyperpigmented macules in 54 pediatric cases [J]. Journal of Clinical Pediatrics, 2025, 43(8): 610-614.
[4]	Chinese Cooperative Group for the Management of Pediatric Enuresis Affiliated to Pediatric Nephrology Committee of Chinese Medical Doctor Association. Chinese expert consensus on management of nocturnal enuresis in children [J]. Journal of Clinical Pediatrics, 2025, 43(7): 483-499.
[5]	WANG Yingshuo, CHEN Zhimin. Leveraging digital intelligence to enhance the diagnosis, treatment, and management of pediatric bronchial asthma [J]. Journal of Clinical Pediatrics, 2025, 43(7): 500-504.
[6]	ZHAO Linchao, WANG Yingjie, JING Zhaohe, MAI Yumiao, SUN Pan, QIU Simin, NIU Hongyun, CHEN Zhiwei, DONG Pengpeng, LIU Jian. Analysis of the efficacy and prognosis of hematopoietic stem cell transplantation for inherited bone marrow failure syndrome in children [J]. Journal of Clinical Pediatrics, 2025, 43(7): 505-510.
[7]	ZHANG Zhiqi, XIONG Ruolan, LI Bohan, JI Qi, WANG Qingwei, LU Jun, LI Jie, XIAO Peifang, HU Shaoyan. Construction of risk prediction model for primary graft failure after umbilical cord blood transplantation in pediatric leukemia [J]. Journal of Clinical Pediatrics, 2025, 43(7): 511-518.
[8]	JIANG Wenwen, LI Sitong, XU Yongsheng. Analysis on risk factors associated with false-negative results of interferon-gamma release assay in children with pulmonary tuberculosis [J]. Journal of Clinical Pediatrics, 2025, 43(7): 519-524.
[9]	LI Fan, HUANG Xianjie, FAN Yazhen, ZHAO Jianchuang, CUI Chenhang, GUO Qiliang, QIAO Junying. Tocilizumab treatment for febrile infection-related epilepsy syndrome in children: 2 cases report and literature review [J]. Journal of Clinical Pediatrics, 2025, 43(7): 532-538.
[10]	DUAN Haolin, ZHANG Ciliu, XIONG Juan, PANG Nan, YIN Fei, PENG Jing. Clinical efficacy analysis of disease-modifying therapies for spinal muscular atrophy with SMN1 gene compound heterozygous variants [J]. Journal of Clinical Pediatrics, 2025, 43(7): 543-548.
[11]	HE Shuang, XU Xin, ZHOU Xue, LIU Qian, ZHANG Lei, TIAN Jie, LYU Tiewei. Leadless cardiac pacemaker implantation via the internal jugular vein: clinical practice and reflection of a 15kg child with third-degree atrioventricular block after congenital heart surgery [J]. Journal of Clinical Pediatrics, 2025, 43(7): 549-553.
[12]	LI Fen. Promoting the research and application of leadless cardiac pacemakers in children [J]. Journal of Clinical Pediatrics, 2025, 43(7): 554-555.
[13]	LYU Mingjun, LUO Wen, YANG Jinxiang, LIANG Jianying, YAO Zhirong. Progress in pathogenesis and treatment of pediatric generalized pustular psoriasis [J]. Journal of Clinical Pediatrics, 2025, 43(7): 556-562.
[14]	ZHANG Hongwen. Application and consideration of eculizumab in the treatment of childhood systemic lupus erythematosus [J]. Journal of Clinical Pediatrics, 2025, 43(6): 403-407.
[15]	LI Qiuyu, LIU Fei, ZHAO Manli, GU Weizhong, FENG Chunyue, FU Haidong. Clinicopathological analysis of 3496 pediatric patients with renal disease: a single-center retrospective study [J]. Journal of Clinical Pediatrics, 2025, 43(6): 411-417.